Lexiva Related Published Studies
Well-designed clinical trials related to Lexiva (Fosamprenavir)
Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial. [2010.09]
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients. [2010.04]
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. [2010.03]
The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers. [2010]
Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naive HIV-1-infected adult subjects. [2009.11]
Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects. [2009.08]
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. [2009.08]
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758. [2009.04]
Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks. [2009.03]
Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials. [2008.12]
Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women. [2007.11]
Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir. [2007.06.19]
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. [2006.08.05]
Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir. [2006.08]
Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV. [2006.04]
Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir. [2006.03]
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. [2005.01.28]
Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. [2005.01]
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. [2004.07.23]
Well-designed clinical trials possibly related to Lexiva (Fosamprenavir)
Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: a mixed treatment comparison. [2011.07]
Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials. [2011.04.01]
Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study. [2010.02.23]
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study. [2009.07]
GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. [2004.03.05]
The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. [2004.01.01]
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. [2004.01]
Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. [2002.08]
Other research related to Lexiva (Fosamprenavir)
Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study). [2011.08]
Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients. [2011.07]
Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients. [2011.02.24]
Food-dependent disintegration of immediate release fosamprenavir tablets: in vitro evaluation using magnetic resonance imaging and a dynamic gastrointestinal system. [2011.02]
Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers. [2010.10]
Long-term efficacy and safety of fosamprenavir in human immunodeficiency virus-infected pediatric patients. [2010.06]
Fosamprenavir treatment in a highly active antiretroviral therapy schedule induces a HCV-RNA decrease and a Th1 network boost in HIV/HCV-coinfected patients. [2010.06]
[Adverse reactions of atazanavir, fosamprenavir and tipranavir in "real life"] [2010.03]
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir
or fosamprenavir given once daily with tenofovir/emtricitabine in
antiretroviral-naive HIV-infected patients. [2010]
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of
unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate
in healthy volunteers. [2010]
Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment. [2009.12]
Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II). [2009.05]
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. [2009.03]
Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program. [2009.01]
Optimal fosamprenavir regimen to prevent lipid abnormalities. [2009]
Genotypic resistance analysis of the virological response to fosamprenavir/ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials. [2008.10.13]
Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens. [2008.09]
Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naive patients with HIV-1 infection. [2008.08]
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects. [2008.07]
Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir. [2008.06]
Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. [2008.06]
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. [2008.03.28]
Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. [2008.02]
Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus. [2008.01]
Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients. [2008]
Pharmacokinetic Interaction between Fosamprenavir/Ritonavir and Rifabutin in Healthy Subjects. [2007.12.03]
Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. [2007.11]
Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state. [2007.10]
Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. [2007.10]
Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. [2007.10]
Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged. [2007.08]
Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects. [2007.06.19]
Fosamprenavir calcium plus ritonavir for HIV infection. [2007.06]
Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients. [2007.04]
Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. [2007.02]
Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz. [2007]
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors. [2007]
Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects. [2006.09]
Fosamprenavir: drug development for adherence. [2006.07]
Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. [2006.05]
Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. [2006.05]
Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. [2006.05]
Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. [2006.04]
Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. [2006]
Salvage therapy with ritonavir-boosted amprenavir/fosamprenavir: virological and immunological response in two years follow-up. [2005.03]
Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. [2005]
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. [2004.11.01]
Fosamprenavir: advancing HIV protease inhibitor treatment options. [2004.09]
Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. [2004]
Fosamprenavir. Vertex Pharmaceuticals/GlaxoSmithKline. [2002.03]
Other possibly related research studies
Peptidomimetic inhibitors of HIV protease. [2004]
Initial therapy for human immunodeficiency virus: broadening the options. [2004.03]
Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. [2004.04.09]
Gateways to clinical trials. [2005.07]
[New antiretroviral treatment modalities] [2005.06.04]
Gateways to clinical trials. [2004.10]
Pharmacokinetics of antiretrovirals in pregnant women. [2004]
Gateways to clinical trials. [2004.09]
Pharmacologic perspectives for once-daily antiretroviral therapy. [2004.11]
Gateways to clinical trials. [2004.06]
Gateways to clinical trials. [2004.04]
New anti-HIV protease inhibitors provide more treatment options. [2003.11]
Prodrugs of HIV protease inhibitors. [2003]
Gateways to clinical trials. [2003.06]
Gateways to clinical trials. [2003.04]
Gateways to clinical trials. [2003.01]
Discovery of next generation inhibitors of HIV protease. [2005]
New antiretroviral drugs in clinical use. [2006.04]
Gateways to clinical trials. [2006.04]
Antiretroviral treatment of HIV infection: Swedish recommendations 2005. [2006]
Emerging anti-HIV drugs. [2005.05]
An update and review of antiretroviral therapy. [2006.08]
Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy. [2006]
Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia. [2006]
|
